Press Releases & News
AMNICELL awarded ‘Best Regenerative Medicine Technology Developers – USA’ by GHP Biotechnology Awards
April 2020, New York – AMNICELL awarded ‘Best Regenerative Medicine Technology Developers – USA’ by GHP Biotechnology Awards
We are very pleased to share that AMNICELL is the recipient of the ‘Best Regenerative Medicine Technology Developers – USA’ by GHP Biotechnology Awards.
The GHP recognizes all levels and aspects of the healthcare and pharmaceutical sectors without whom many life changing innovations and developments would not be possible. Their rewards and awards recognize those whose tireless work and dedication change the lives of millions of people each and every day. GHP is dedicated to uncovering and sharing the talented courageous, and innovative people, departments and companies pushing the boundaries of what is possible in the medical world.
Best Regenerative Medicine Technology Developers – USA
Dr. Bruce K. Young awarded Albert Nelson Marquis Lifetime Achievement Award in recognition for outstanding accomplishments
New York, March 2020 – World renowned Obstetrician and Gynecologist and Founder of AMNICELL, Dr. Bruce K. Young has been awarded the prestigious Albert Nelson Marquis Lifetime Achievement Award in recognition for his outstanding accomplishments throughout his career at New York University Langone Medical Center.
Dr. Young has held numerous positions while at NYU Medical Center, including Director of Obstetrical Services, Chief of Obstetrics at Bellevue Hospital, Head of Pregnancy Loss Prevention Center and Associate Director of Department, as well as Founder and Director of Division of Maternal and Fetal Medicine. He has continuously trained medical students, residents and fellows as Professor of Obstetrics and Gynecology at New York University School of Medicine, rising to the rank of full Professor in 1980, and Silverman Endowed Professor in 1986.
He is an internationally recognized innovator and leader in his field and his clinical research has resulted in 150 peer review scientific publications. He has edited scientific books, contributed with chapters to 12 books, written 2 books for general public, served as editor for scientific journals, given numerous lectures world-wide and appeared on television programs. He is the recipient of numerous awards and honors, including the Outstanding Achievement Award of American College of Obstetricians and Gynecologists, Outstanding Service in Education and Distinguished Service Award in Fight Against Birth Defects from March of Dimes-National Foundation, and Berson Award in Clinical Science from New York University School of Medicine, among many others.
Dr. Young is a graduate of Princeton University and New York University School of Medicine. Board certified in Obstetrics and Gynecology and Maternal-Fetal Medicine, he was the Director of Examinations for American Board of Obstetrics and Gynecology Division of Maternal-Fetal Medicine for 10 years. Besides the American Board, his professional memberships include the American Gynecological and Obstetrical Society, past President of NY Obstetrical Society, Perinatal Society, NYU School of Medicine Alumni Association, Founder and Director of the Society for Maternal-Fetal Medicine, Royal Society of Medicine in England, and Alpha Omega Alpha Honor Medical Society.
He continues his teaching and research at New York University Langone Medical Center today, while also focusing on the potential of stem cells and regenerative medicine in AMNICELL to heal wounds, treat diabetes, lung fibrosis, and Alzheimer’s Disease.
“I am delighted to receive this award recognizing my achievements. The past is the prologue though; in the present and the future I look forward to building on the past and successfully grow AMNICELL in regenerative medicine, bringing innovation in both therapeutics and cosmeceuticals” says Dr. Bruce K. Young.
AMNICELL joins JP Morgan Healthcare Conference 2020 in San Francisco
San Francisco, January 2020 – AMNICELL’s CEO Helen Ljungdahl Round and Chief Science Officer Dr Bruce K Young joined more than 9,000 health care leaders and investors at the annual JPM Healthcare Conference in San Francisco, January 13-16, 2020.
The annual JP Morgan Healthcare Conference is the largest healthcare investment event in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. The conference started back in 1983 with 20 companies and 200 attendees focusing on the biotech industry. Today, it brings together thousands of investors and companies from around the world. The conference covers the full global healthcare landscape, including start-ups, pharmaceutical and biotech companies, healthcare service providers, profit and not-for-profit organizations, as well as medical device companies.
The JP Morgan Healthcare Conference provides AMNICELL with an important opportunity to meet with potential investors and continuing positioning AMNICELL as the first and leading company working with amniotic fluid cell therapy, and bringing the latest technology in regenerative medicine to overcome unmet medical needs and contribute to health and wellness.
AMNICELL joins Biotech Week Boston in September
Boston, Sept 2019 – AMNICELL’s CEO Helen Ljungdahl Round and Chief Science Officer Dr Bruce K Young will join 4,500 life science leaders, scientists and innovators at Biotech Week Boston, September 9-12, 2019.
Biotech Week Boston is uniquely positioned to accelerate the development of biotechnology through an exchange of new ideas, science, technology and partnerships, all with the focus on driving a positive impact on health evolution and improving patient health. BioPharm America, taking place on September 11-12, focuses on highlighting innovations as well as promoting new business relationships by bringing companies across the life science ecosystem together to engage in drug development collaborations. Life science executives from around the world will gather to identify, meet and to enter into strategic relationships.
Biotech Week Boston provides an important opportunity to continue positioning AMNICELL as a leader in amniotic fluid stem cell therapy, and bringing the latest technology in regenerative medicine to overcome unmet medical needs and contribute to health wellness.
AMNICELL appoints Helen Ljungdahl Round as CEO
New York, USA Aug 27, 2019 – AMNICELL, a biotech company focusing on research and development of amniotic fluid stem cells, today announced that Helen Ljungdahl Round has been appointed as CEO, effective July 1, 2019.
AMNICELL is the first company to use advanced stem cell technology, amniotic fluid and pluripotent stem cells to improve lives, health and wellness. The company was formed following 10 years of research with amniotic fluid and stem cells. The amniotic fluid is a unique non-controversial abundant source of stem cells with regenerative properties. AMNICELL collects, stores and processes the amniotic fluid and the stem cells for use in areas of unmet medical need and commercial areas, such as hair and skin care,
Helen Ljungdahl Round is a highly accomplished executive with more than 25 years of experience in international business management, strategy, marketing and sales in the pharmaceutical and medical technology industries, across numerous therapeutic areas, product life cycles and geographic areas. Her wealth of professional and business experience includes positions as Senior Vice President of Global Marketing & Business Development for GN Hearing, and, before that, numerous executive leadership positions of increasing responsibility at Merck & Co, Inc, working in EU, Middle East/Africa, North America, Latin America and Asia. She is a strong commercial leader that has consistently built high performing organizations and delivered profitable and sustainable business results.
Dr Bruce K Young, Professor at NYU School of Medicine, Chairman of AMNICELL Board of Directors, commented: “I am very excited that we have been able to attract someone like Helen Ljungdahl Round as the CEO of AMNICELL. With her experience from the pharmaceutical and medical technology industries, and leading highly successful global commercial organizations around the world, she is the perfect person to lead AMNICELL through the development of our unique technology and product portfolio, as well as delivering strong business results”.
Helen Ljungdahl Round said: “Regenerative medicine holds a lot of future potential, and AMNICELL is uniquely positioned with its advanced technology using amniotic fluid and pluripotent stem cells to contribute to this development. Our initial focus will be on areas of unmet medical need, but also other areas benefiting from the regenerative properties of amniotic fluid and stem cells. I am looking forward to continuing the science, developing our product portfolio, and more importantly bringing these transformative products to the market, enabling people access to novel biological solutions for their health and wellness”.
AMNICELL is the first company to use advanced stem cell technology, amniotic fluid and pluripotent stem cells to improve lives, health and wellness. The company is based on more than 10 years research with amniotic fluid and stem cells, and the primary focus on the development and commercialization of transformative therapeutics and innovative cosmeceuticals. AMNICELL is headquartered in New York City and is privately owned.
Global Experts Meeting on Frontiers in Cell & Stem Cell Research, in New York
New York, April 2019 – Dr. Bruce K Young presented as Key Note Speaker at the Global Experts Meeting on Frontiers in Cell & Stem Cell Research on the topic of ‘Clinical Potential of Human Amniotic Fluid Stem Cells’.
He shared the results of a study designed to characterize full term amniotic fluid stem cells and compare them with previously described mid-trimester amniotic fluid stem cells. Stem cells are undifferentiated cells with the ability to self-replicate without differentiation. Mid-trimester amniotic fluid stem cells have been well-characterized as multipotent, but scant data exist for full term amniotic fluid. With the advent of non-invasive prenatal diagnosis, mid-trimester amniotic fluid will become less available from normal patients. In contrast, term amniotic fluid is available in large quantities from normal pregnancies and might be a resource for clinical transplantation.
The study confirmed that full term and mid-trimester amniotic fluid stem cells demonstrate similar characteristics. The full term amniotic fluid stem cells were indeed multipotent and they differentiated into multiple cell lineages. They also tolerate and remain unchanged during cryostorage. Previous studies on term fluid have demonstrated only mesenchymal cells that required induction to pluripotent stem cells to achieve differentiation to neural lineage. Induced pluripotent cells are genomically unstable and tumorigenic; amniotic stem cells are not. This study demonstrates for the first time that both ectodermal and mesenchymal differentiability are present in term amniotic fluid stem cells. Neural differentiation was achieved without the induction of pluripotency. Term amniotic fluid contains approximately 1 million cells per milliliter, which may represent a readily available, abundant, and noncontroversial source of stem cells with therapeutic potential.
AMNICELL is the first company to develop amniotic fluid and stem cells for treating non-healing wounds, as well as products for skin care and hair growth.
16th Annual Meeting of the Society for Reproductive Investigation, in Paris, France
Paris, France March 2019 – Dr. Bruce K Young presented on “Could Trisomy 21 (T21) Brains be Enhanced?” at the 16th Annual Meeting of the Society for Reproductive Investigation (SRI), March 12-16 in Paris, France.
This year the conference theme was “From Innovation to Impact”, highlighting the Society’s dedication to world-class innovation in basic research and translational medicine, as well as to improvements in women’s reproductive health and healthcare.
The study results presented by Dr Young showed the enhancement of neurological differentiation and gene expression specific to neural development by dexamethasone (DX) administration to cultured amniotic fluid stem cells from 1 of 5 trisomy 21 (Down Syndrome) fetuses. Previous studies by Dr Young’s team using human amniotic fluid derived stem cells demonstrated a potential for enhanced fetal brain development by administration of DX to amniotic fluid derived stem cells from euploid fetuses. This study found a specific genome which may identify T21 fetuses whose neurological development could be improved with DX therapy. Down Syndrome children who grow to adulthood suffer from early onset of severe Alzheimer’s Disease due to deposition of amyloid protein in the brain. The gene for amyloid was suppressed in the cells responding to DX, possibly offering some Alzheimer’s patients potential benefit from DX therapy.
This study is the first to discover a gene pattern in Down Syndrome that describes a possible method to treat Down Syndrome in utero as well as Alzheimer’s disease.